CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Tibolone

替勃龙 杂质对照品Tibolone Impurities

EP19 个杂质条目19 impurity entries

本页汇总 替勃龙 的 19 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 19 impurity reference standards of Tibolone with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 替勃龙(Tibolone)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 分析方法Analytical MethodsApplication of UPLC-MS/MS for separation and quantification of 3α-Hydroxy Tibolone and comparative bioavailability of two Tibolone formulations in healthy volunteers
    Journal of pharmaceutical analysis · 2013 · Shinde VP et al.  ·  PMID 29403827  ·  DOI
  2. 分析方法Analytical MethodsDetermination of 3-α-hydroxytibolone in human plasma by LC-MS/MS: application for a pharmacokinetic study after administration of a tibolone formulation
    Biomedical chromatography : BMC · 2013 · de Santana e Silva Cardoso FF et al.  ·  PMID 23813413  ·  DOI
  3. 分析方法Analytical MethodsImproved detectability in pharmacokinetic study of tibolone by gas chromatography-high resolution mass spectrometry with selected ion monitoring
    Talanta · 2006 · Son J et al.  ·  PMID 18970725  ·  DOI
  4. 分析方法Analytical MethodsConversion of tibolone to 7alpha-methyl-ethinyl estradiol using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry: interpretation and clinical implications
    Menopause (New York, N.Y.) · 2006 · Zacharia LC et al.  ·  PMID 17006378  ·  DOI

替勃龙 —— 原料药与杂质对照品Tibolone — drug substance & impurities

共 19 个条目(含原料药本体)19 items incl. the drug substance
Tibolone  Impurity 3(Tibolone EP Impurity C) structure
EPC
替勃龙杂质3(替勃龙EP杂质C)Tibolone Impurity 3(Tibolone EP Impurity C)
Tibolone Impurity 3(Tibolone EP Impurity C)
CAS No.155239-50-2
Chemical FormulaC21H28O2
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone  Impurity 4(Tibolone EP Impurity D) structure
EPD
替勃龙杂质4(替勃龙EP杂质D)Tibolone Impurity 4(Tibolone EP Impurity D)
Tibolone Impurity 4(Tibolone EP Impurity D)
CAS No.32297-45-3
Chemical FormulaC21H28O2
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone  Impurity 5(Tibolone EP Impurity E) structure
EPE
替勃龙杂质5(替勃龙EP杂质E)Tibolone Impurity 5(Tibolone EP Impurity E)
Tibolone Impurity 5(Tibolone EP Impurity E)
CAS No.105186-33-2
Chemical FormulaC23H34O3
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone  Impurity 6 structure
6
替勃龙杂质6Tibolone Impurity 6
Tibolone Impurity 6
CAS No.88247-84-1
Chemical FormulaC21H32O3
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone  Impurity 7 structure
7
替勃龙杂质7Tibolone Impurity 7
Tibolone Impurity 7
CAS No.105186-35-4
Chemical FormulaC21H28O3
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone  Impurity 8 structure
8
替勃龙杂质8Tibolone Impurity 8
Tibolone Impurity 8
CAS No.15506-02-2
Chemical FormulaC20H30O2
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone  Impurity 9 structure
9
替勃龙杂质9Tibolone Impurity 9
Tibolone Impurity 9
CAS No.105186-34-3
Chemical FormulaC21H28O4
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone  Impurity 10 structure
10
替勃龙杂质10Tibolone Impurity 10
Tibolone Impurity 10
CAS No.677299-58-0
Chemical FormulaC23H32O3
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone  Impurity 11 structure
11
替勃龙杂质11Tibolone Impurity 11
Tibolone Impurity 11
CAS No.26674-51-1
Chemical FormulaC22H30O2
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone  Impurity 12 structure
12
替勃龙杂质12Tibolone Impurity 12
Tibolone Impurity 12
CAS No.300542-58-9
Chemical FormulaC23H32O2Si
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone Impurity 13 structure
13
替勃龙杂质13Tibolone Impurity 13
Tibolone Impurity 13
CAS No.1162-60-3
Chemical FormulaC21H28O2
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone Impurity 14 structure
14
替勃龙杂质14Tibolone Impurity 14
Tibolone Impurity 14
CAS No.100239-44-9
Chemical FormulaC21H30O2
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone Impurity 15 structure
15
替勃龙杂质15Tibolone Impurity 15
Tibolone Impurity 15
CAS No.100239-45-0
Chemical FormulaC21H30O2
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone Impurity 16 structure
16
替勃龙杂质16Tibolone Impurity 16
Tibolone Impurity 16
CAS No.32297-44-2
Chemical FormulaC22H30O2
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone Impurity 17 structure
17
替勃龙杂质17Tibolone Impurity 17
Tibolone Impurity 17
CAS No.15506-05-5
Chemical FormulaC22H30O2
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone Impurity 18 structure
18
替勃龙杂质18Tibolone Impurity 18
Tibolone Impurity 18
CAS No.144466-05-7
Chemical FormulaC21H30O5S
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone Impurity 19 structure
19
替勃龙杂质19Tibolone Impurity 19
Tibolone Impurity 19
CAS No.144466-06-8
Chemical FormulaC21H30O5S
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone Impurity 21 structure
21
替勃龙杂质21Tibolone Impurity 21
Tibolone Impurity 21
CAS No.77579-37-4
Chemical FormulaC21H26O2
Purity>95%询价On request
10mg25mg50mg100mg
Tibolone Impurity 22 structure
22
替勃龙杂质22Tibolone Impurity 22
Tibolone Impurity 22
CAS No.1173998-66-7
Chemical FormulaC20H34O2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

替勃龙 —— 研究文献与合成路线Tibolone — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 替勃龙 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Tibolone. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Tibolone inhibits bone resorption without secondary positive effects on cartilage degradation
    Karsdal MA, Byrjalsen I, Leeming DJ, et al. · BMC musculoskeletal disorders · 2008 · 被引 24cited 24
  2. Pharmaceutical tablets containing tibolone and a coating, which reduces the formation of the tibolone-derived isomerisation degradation product OM38
    DE HAAN PIETER, VAN LARE CORNELIS ELISABETH JO · 2006
  3. PHARMACEUTICAL COMPOSITIONS CONTAINING SYNTHETIC STEROID DERIVATIVES SUCH AS TIBOLONE, MINERALS SUCH AS CALCIUM AND THE ACTIVE METABOLITE OF VITAMIN D (CALCITROL) FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS AND MENOPAUSE
    GARCIA ARMENTA MARIA ELENA, ALVAREZ OCHOA VICTOR GUILLERMO, SANTOS MURILLO JOSEFINA, et al. · 2008

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR THE PREPARATION OF PURE CRYSTALLINE TIBOLONE
    CARICATO GIUSEPPE, BOSEGGIA ELISA, COLETTI MONICA · 公开号 EP1883648EP1883648 · 2008
  2. PROCESS FOR THE PREPARATION OF PURE CRYSTALLINE TIBOLONE
    CARICATO Giuseppe, BOSEGGIA Elisa, COLETTI Monica · 公开号 WO2006125453WO2006125453 · 2006
  3. Process for the produciton of tibolone
    GREENWOOD ALAN K, MCHATTIE DEREK, BHATARAH PARVEEN · 公开号 US2006173201US2006173201 · 2006
  4. Process for the preparation of free flowing pulverized adsorbates of tibolone
    GLAENZER KLAUS · 公开号 US2005176679US2005176679 · 2005
  5. Process for the production of tibolone
    KENNETH GREENWOOD ALAN, DEREK MCHATTIE, PARVEEN BHATARAH · 公开号 ZA200507281ZA200507281 · 2006

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

替勃龙 杂质谱研究要点Tibolone — impurity profiling notes

下面这些是拿到 替勃龙 的 19 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 19 impurity entries for Tibolone, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances